A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Inclusion Criteria:

- Have type 2 diabetes mellitus (T2DM) for at least 6 months

- Have been treated with stable metformin dose for at least 3 months

- Have HbA1c ≥7.5% and ≤11.0% at study entry

- Have body mass index (BMI) ≥25 kilograms per meter squared (kg/m^2)

Exclusion Criteria:

- Have type 1 diabetes mellitus

- Have used any glucagon-like peptide-1 receptor agonist (GLP-1 RA) or insulin, not
including prior short term insulin use (≤14 days)

- Have been taking any other medicine for diabetes (other than metformin) during the
last 3 months

- Have used in the last 3 months (or plan to use) prescription weight loss medications

- Have disorders associated with slowed emptying of the stomach contents, or have had
any stomach surgeries for the purpose of weight loss

- Current participation in or intent to begin during the study an organized diet and/or
exercise weight reduction program (other than the lifestyle and dietary measures for
diabetes)

- Have acute or chronic hepatitis, signs and symptoms of any other liver disease other
than nonalcoholic fatty liver disease (NAFLD), or alanine transaminase (ALT) level
>2.5 times the upper limit of the reference range, as determined by the central
laboratory at study entry; participants with NAFLD are eligible for participation in
this trial

- Had chronic or acute pancreatitis any time prior to study entry

- Have had a heart attack or stroke in the past 2 months, or have heart failure that
significantly limits their physical activity

- Estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73m^2 (or lower
than the country-specific threshold for discontinuing metformin therapy per local
label), calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, as
determined by the central laboratory at study entry and confirmed at lead-in

- Have a personal or family history of medullary thyroid carcinoma or personal history
of multiple endocrine neoplasia syndrome type 2

- Have proliferative retinopathy or maculopathy requiring acute treatment according to
the opinion of the investigator